Fidelity Investments’s Xenetic Biosciences XBIO Stock Holding History

Fidelity Investments’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1	Closed	-$5	–	5674
2023 Q3	$5	Sell	1 -6	-86%	-$25	﹤0.01%	5227
2023 Q2	$22	Sell	7 -15	-68%	-$56	﹤0.01%	5164
2023 Q1	$89	Buy	22 +20	+1,000%	+$97	﹤0.01%	4917
2022 Q4	$5	Hold	2	–	–	﹤0.01%	5294
2022 Q3	$0	Sell	2 -1	-33%	-$8	﹤0.01%	5464
2022 Q2	$0	Buy	+3	New	+$24	﹤0.01%	5545

Other funds holding XBIO

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments's XBIO Position: Q4 2023 in Review

Fidelity Investments sold out of Xenetic Biosciences (XBIO) in Q4 2023, closing a stake of 1 share — an estimated $5 sold.

Fidelity Investments first reported a position in XBIO in Q2 2022 and held it in 6 quarters. The position peaked at $89 in Q1 2023. 7 funds tracked by Wall St. Rank hold XBIO as of Q4 2023.

Fidelity Investments reported no remaining Xenetic Biosciences position as of Q4 2023 after selling out during the quarter.
Fidelity Investments sold 1 Xenetic Biosciences share in Q4 2023, an estimated $5.
Fidelity Investments first reported a position in Xenetic Biosciences in Q2 2022 and held it in 6 quarters.
Fidelity Investments's Xenetic Biosciences position peaked at $89 in Q1 2023.
7 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q4 2023.

Based on Fidelity Investments's 13F filing for Q4 2023, filed 13 Feb 2024.